Tag Archives: Institute of Cancer Research Joins International Trial of Novel Oncolytic Immunotherapy for Platinum-Resistant Ovarian Cancer

€8 Million Horizon Europe Grant Supports Clinical Development of Theolytics Oncolytic Virus Therapy for Advanced Ovarian Cancer

(IN BRIEF) Scientists at the Institute of Cancer Research in London are contributing to an international clinical trial evaluating THEO-260, an experimental oncolytic immunotherapy designed to treat platinum-resistant ovarian cancer. The trial, known as OCTOPOD-IV, is being supported by €8 … Read the full press release